Inhibition of the protein kinase ATR, which is a critical regulator of the ALT pathway, selectively kills ALT-positive gliomas, and the brain-penetrant ATR inhibitors berzosertib and AZD6738 are currently in clinical trials for solid tumors15. Here, ATR is linked to central nervous system cancer.